Results 11 to 20 of about 231,548 (147)

Repeated Treatment With the Traditional Medicine Unsei-in Inhibits Substance P-Induced Itch-Associated Responses Through Downregulation of the Expression of Nitric Oxide Synthase 1 in Mice

open access: yesJournal of Pharmacological Sciences, 2004
Unsei-in inhibits substance P (SP)-induced scratching of mice after repeated administration. The involvement of cutaneous nitric oxide (NO) in the SP-induced scratching led us to investigate the effects of Unsei-in on the cutaneous NO system in mice ...
Tsugunobu Andoh   +4 more
doaj   +1 more source

Induction of chronic migraine phenotypes in a rat model after environmental irritant exposure [PDF]

open access: yes, 2017
Air pollution is linked to increased emergency department visits for headache and migraine patients frequently cite chemicals or odors as headache triggers, but the association between air pollutants and headache is not well understood.
Hurley, Joyce Harts   +4 more
core   +1 more source

Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma

open access: yesFrontiers in Oncology, 2018
Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma.
Taku Fujimura   +21 more
doaj   +1 more source

Combined pulsed-dye laser and medical therapy for treatment of cutaneous sarcoidosis lesions: a case report

open access: yesJournal of International Medical Research, 2021
Sarcoidosis is a systemic granulomatous disease of unknown etiology that most frequently occurs in the lungs. However, cutaneous lesions are often the primary sign.
Wenxin Dong   +3 more
doaj   +1 more source

Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma. [PDF]

open access: yes, 2014
BackgroundCanine cutaneous T-cell lymphoma (CTCL) is an uncommon disease for which efficacious therapies are lacking. The novel anticancer nucleotide prodrug VDC-1101 (formerly known as GS-9219) has shown efficacy in dogs with multicentric lymphoma.
Burgess, KE   +5 more
core   +2 more sources

Acute Hepatic Porphyrias: Review and Recent Progress. [PDF]

open access: yes, 2019
The acute hepatic porphyrias (AHPs) are a group of four inherited diseases of heme biosynthesis that present with episodic, acute neurovisceral symptoms.
Andant   +40 more
core   +1 more source

Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection [PDF]

open access: yes, 2014
Background/Purpose: A proper adjuvant has a relevant role in vaccine formulations to generate an effective immune response. In this study, total Leishmania antigen (TLA) formulated with Montanide ISA 763 or R848 as adjuvants were evaluated as a first ...
Cargnelutti, Diego Esteban   +6 more
core   +1 more source

Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. [PDF]

open access: yes, 1990
BALB/c mice infected with Leishmania major develop fatal, progressive disease, despite an immune response characterized by expansion of CD4+ T cells in the draining lymph nodes.
Dawkins, RS   +5 more
core   +1 more source

Nanoparticulate Gels for Cutaneous Administration of Caffeic Acid

open access: yesNanomaterials, 2020
Caffeic acid is a natural antioxidant, largely distributed in plant tissues and food sources, possessing anti-inflammatory, antimicrobial, and anticarcinogenic properties.
Maddalena Sguizzato   +11 more
doaj   +1 more source

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program [PDF]

open access: yes, 2019
Background: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval.
Buti, S   +22 more
core   +3 more sources

Home - About - Disclaimer - Privacy